CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Throat swabWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1758 Pandemic control measures Wiki 1.00
drug386 Blood sampling Wiki 0.58

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D003866 Depressive Disorder NIH 0.24
D001008 Anxiety Disorders NIH 0.17
D003863 Depression, NIH 0.15

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000716 Depressivity HPO 0.24

There is one clinical trial.

Clinical Trials


1 A Prospective, Epidemiological, Cohort Study to Assess the Feasibility of Screening Healthy Asymptomatic Workers for the Presence of SARS-CoV-2 by Pharyngeal Swaps and Serology at Baseline, Day 21 and Day 40

This is a prospective, epidemiological, cohort study to assess the feasibility of screening healthy asymptomatic workers for the presence of severe acute respiratory syndrome SARS-CoV-2 by pharyngeal swaps and serology at baseline, day 21 and day 40.

NCT04405466 COVID-19 Procedure: Blood sampling Procedure: Throat swab

Primary Outcomes

Description: Evaluation of immune responses to components of SARS-CoV-2 as well as evaluation of Swab for the presence of SARS-CoV-2 by PCR. Determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status. Analysis of trends in CD4/CD8 concentrations over time and correlation with immunoglobulin G (IgG) Levels and new assay evaluation.

Measure: Immune responses to components of SARS-Cov-2

Time: up to visit 3 (day 40)

Description: Evaluation of Swab for the presence of SARS-CoV-2 by PCR and determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status.

Measure: Swabs for the presence of SARSCoV-2

Time: up to visit 3 (day 40)

Secondary Outcomes

Description: Evaluation of immune responses to components of SARS-CoV-2 as well as evaluation of Swab for the presence of SARS-CoV-2 by PCR. Determination of the difference between the study groups in anti-SARS-CoV 2 seropositivity status and analysis of trends in CD4/CD8 concentrations over time and correlation with IgG Levels as well as new assay evaluation.

Measure: Difference between the study groups in anti-SARS-CoV 2 seropositivity status

Time: up to visit 3 (day 40)


No related HPO nodes (Using clinical trials)